GHK-Cu: Copper Tripeptide Research Guide (2026)
Last updated
Introduction (research-only scope)
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a fragment that occurs naturally in human plasma and whose concentration declines with age. It is one of the most studied small peptides in tissue-remodelling and gene-expression research, and one of the few in this catalog with a large in-vitro literature that is independent of any single originating company. This guide covers what it is, what the literature reports, and how to source and verify research-grade material.
Research use only. The material described here is a laboratory reagent for in-vitro research by qualified professionals. It is not a medicine, supplement, cosmetic ingredient or veterinary product, is not for human or animal use, and nothing on this page is medical advice or a claim of effect in any person.
What is GHK-Cu?
The free tripeptide GHK (molecular mass 340.38, CAS 300801-03-0 for the copper complex as catalogued) binds copper(II) with high affinity, and it is the copper complex that carries most of the reported biological activity. It was first isolated from human plasma in the 1970s by Loren Pickart, whose group has since published the bulk of the mechanistic literature. Peptra Labs supplies GHK-Cu as a lyophilised research reagent, 50 mg per vial.
How the reported mechanism works
Copper delivery and metalloenzymes
GHK-Cu is proposed to shuttle copper into cells and to copper-dependent enzymes such as lysyl oxidase and superoxide dismutase; much of the early literature examines it as a copper-delivery vehicle rather than as a signalling peptide in its own right.
Gene-expression signature
The most cited modern work compares GHK against the Broad Institute Connectivity Map and reports that it shifts expression of a large number of human genes, many involved in remodelling, antioxidant defence and DNA repair (Pickart & Margolina, International Journal of Molecular Sciences, 2018). Those are computational and in-vitro findings, not clinical outcomes.
Extracellular matrix remodelling
In cultured fibroblasts and animal wound models GHK-Cu has been reported to modulate collagen, glycosaminoglycan and metalloproteinase activity; our page on GHK-Cu gene expression goes deeper into the transcriptomic evidence.
What the published evidence covers
The literature is broad in vitro and in animal models and thin in independent human trials; most reviews come from the originating laboratory. Two 2026 papers reported skin-related findings but neither tested the peptide on its own, a distinction we discuss in our news coverage. For a research buyer the useful reading is the 2012 review of oxidative-stress mechanisms and the 2018 gene-data review, both indexed below.
GHK-Cu vs other copper and remodelling peptides
GHK-Cu is often grouped with cosmetic peptides (palmitoyl pentapeptides, argireline) that fall under cosmetics regulation when used topically. As a research reagent it is studied alongside BPC-157 and TB-500 in tissue-repair models, but its mechanism, copper-mediated and transcriptomic, is distinct from both.
How to verify a GHK-Cu research peptide is real and pure
Identity is confirmed by mass spectrometry, purity by HPLC. Our specification is at least 98% purity. The published report for batch QYA055 (tested 20 March 2026) reported 99.8% purity and can be checked on the testing laboratory’s platform: Janoshik verification 121492. Match the batch number on your vial against the lab reports archive; see how to read a certificate of analysis.
Storage and reconstitution specific to GHK-Cu
The lyophilised copper complex has a characteristic blue colour and is stable sealed, dry and protected from light at 2 to 8 °C. Reconstituted solutions should be kept refrigerated and used within the window your protocol defines; copper complexes are sensitive to chelating buffers, so buffer choice matters in assay design. General handling is in the peptide storage protocol.
Regulatory status
GHK-Cu is not an authorised medicine anywhere; it appears as an ingredient in cosmetics regulated under EU Regulation 1223/2009 when used topically. Research-grade material supplied here is not a cosmetic product and not for human or animal use. It is not named on the WADA Prohibited List. See the peptide risk profile for the framework.
Why labs choose our GHK-Cu
A batch-tested reagent (QYA055: 99.8%), 50 mg per vial, shipped from an EU warehouse with tracking, VAT included. Product page: GHK-Cu 50 mg; buyer guide: Buy GHK-Cu in Europe.
References
- Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Oxid Med Cell Longev. 2012. PubMed 22666519
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. PubMed 29986520